Last reviewed · How we verify
Dalvance (DALBAVANCIN)
Dalvance works by binding to the bacterial cell wall, disrupting its synthesis and ultimately leading to cell death.
At a glance
| Generic name | DALBAVANCIN |
|---|---|
| Sponsor | AbbVie |
| Drug class | Lipoglycopeptide Antibacterial |
| Modality | Recombinant protein |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 2014 |
| Annual revenue | 260 |
Mechanism of action
Dalbavancin is an antibacterial drug [see Microbiology 12.4 )].
Approved indications
- Bacterial infection of skin
- Infection of skin AND/OR subcutaneous tissue
- Staphylococcal infection of skin
Common side effects
- Nausea
- Headache
- Diarrhea
- Vomiting
- Rash
- Pruritus
- Pyrexia
- Anemia
- Leucopenia
- Neutropenia
- Thrombocytopenia
- Petechiae
Key clinical trials
- A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia (PHASE1)
- Pathogenicity Factors of Staphylococcus Pettenkoferi in Foot Wounds and Osteitis in Diabetic Patients
- Comparing Oral Versus Parenteral Antimicrobial Therapy (PHASE4)
- Ampicillin and Ceftriaxone for the Treatment of Enterococcus Faecalis Infective Endocarditis. (PHASE4)
- Dalbavancin Versus Standard Antibiotic Therapy for Catheter-related Bloodstream Infections Due to Staphylococcus Aureus (PHASE3)
- Efficacy and Safety of Dalbavancin As Suppressive Therapy
- DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia (PHASE2)
- Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA (PHASE3)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dalvance CI brief — competitive landscape report
- Dalvance updates RSS · CI watch RSS
- AbbVie portfolio CI